TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02340767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Device
Description: Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAGNOdent
Description: DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
Study: NCT01440374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: 100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: 100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: 100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
Study: NCT00924261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Stretch
Description: Hip flexor stretch daily for 3 min x 10 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Stretch
Description: Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
Study: NCT01966380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leia
Study: NCT02070133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg once a day during 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day during 12 weeks
Study: NCT04153123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study: NCT00734383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
Study: NCT00925431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: 16 hours of motivational, lifestyle management session, 8 hours nutritional education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive education
Description: 16 hours general fibromyalgia education, 8 hours of nutritional education
Study: NCT01592500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Once daily subcutaneous injection of Genotropin
Study: NCT03251781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
Study: NCT00690443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: atorvastatin 20 mg tablets, daily dosing, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEGR-733
Description: 2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
Study: NCT04171453

Intervention type: DRUG
Intervention: Lyrica CR (Pregabalin)
Description: Lyrica CR 82.5mg, 165mg, or 330mg OD
Study: NCT02726685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory training.
Description: breathing exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham training.
Description: range of motion (ROM) exercise, stretching exercise or positioning exercise.
Study: NCT01493011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chemotherapy & WBH
Description: standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
Study: NCT01451125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
Study: NCT04017039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Sleep Intervention
Study: NCT00320541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study: NCT03545958

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity Continuous Training (MCT)
Description: After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
Study: NCT00320541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
Study: NCT02401360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: China Crest® Pro-health 7 Complete Toothpaste
Description: Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: China Crest® Cavity Protection Toothpaste
Description: Crest® meliliangje manual toothbrush
Study: NCT03294746

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluations
Description: At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.

Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic CT
Description: At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan\* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
Study: NCT03029312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo M
Description: Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
Study: NCT02263937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Nucleus Basalis Meynert DBS
Description: Low frequency stimulation applied using standard Deep brain stimualtion hardware.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Nucleus Basalis Meynert DBS
Description: DBS system switched off.
Study: NCT00901277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web intervention
Description: A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse intervention
Description: A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
Study: NCT03553368

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HF-NIV-MR
Description: MRI data will be acquired with the use of HF-NIV.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HF-NIV-MR
Description: MRI data will be acquired with the use of HF-NIV.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HF-NIV-MR
Description: MRI data will be acquired with the use of HF-NIV.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HF-NIV-PET
Description: PET data will be acquired with the use of HF-NIV.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR
Description: MRI data will be acquired without the use of any device as a reference.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR
Description: MRI data will be acquired without the use of any device as a reference.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR
Description: MRI data will be acquired without the use of any device as a reference.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MR
Description: MRI data will be acquired without the use of any device as a reference.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT breath hold
Description: PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CPAP-MR
Description: MRI data will be acquired with the use of CPAP.
Study: NCT02522351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal extract concentration 1
Description: Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
Study: NCT03208946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-CML diet
Description: Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-CML diet
Description: Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
Study: NCT02059278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-2345
Description: T-2345 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: Xalatan (latanoprost 0.005% ophthalmic solution)
Study: NCT01907854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: 100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Sitagliptin placebo tablets once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Sitagliptin placebo tablets once-daily
Study: NCT02930863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse oximetry software
Description: This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief post-PACU stay survey.
Description: Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief post-PACU stay survey.
Description: Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
Study: NCT01403610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 preoperative
Description: TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 preoperative
Description: TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 (escalating) with bevacizumab 10mg/kg
Description: Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 (escalating) with bevacizumab 10mg/kg
Description: Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 (escalating) with bevacizumab 10mg/kg
Description: Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 (escalating) with bevacizumab 10mg/kg
Description: Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
Study: NCT03171363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-contingent feedback
Description: Participants will receive gaze-contingent feedback according to their viewing patterns
Study: NCT05657886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half swaddle
Description: Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half swaddle
Description: Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
Study: NCT02913235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene discontinuation group
Description: Discontinuation of regular oral hygiene for 10 days
Study: NCT02207348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
Study: NCT02970331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pefcalcitol ointment, 0.005%
Description: pefcalcitol ointment, 0.005%
Study: NCT00004660

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Study: NCT02391272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Study: NCT04712331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises
Description: Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Russian current stimulation
Description: The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation
Description: Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.